Who We Are: HOPE

HopeinSand
Hope. Patients facing recurrent and refractory ovarian cancer deserve the chance to find the best treatment for their specific cancer. The Clearity Foundation was launched in 2008 to revolutionize ovarian cancer treatment.

Our team is made up of scientists, physicians, and volunteers who are passionate about changing the paradigm for ovarian cancer treatment from a trial-and-error approach to one that individualizes therapy selection based on each patient’s unique tumor molecular profile.

The Clearity Foundation helps eligible women obtain and understand the molecular profile of their tumor. Our profiling approach synthesizes data from multiple sources that measure the levels of specific protein biomarkers and detects certain genetic changes that are relevant in ovarian cancer. The resulting Tumor Blueprint provides information that enables physicians to select drugs that match each patient’s individual disease and may therefore be more effective than other options.

What We Do

The Clearity Foundation is a 501(c)(3) not-for-profit organization providing patient support services including lab test coordination, Tumor Blueprint compilation, interpretation, and clinical trial identification free of charge. We believe that all patients, regardless of means, should have access to the most state-of-the-art care.

Clearity works with three commercial clinical laboratories to conduct tumor profiling and then synthesizes the results in order to provide personalized treatment options for ovarian cancer patients. The foundation has built an extensive clinical and molecular profiling database to interpret the tumor profiles and also enable research dedicated to advancing the treatment of ovarian cancer.

Our services and educational programs are focused on:

  • Assisting patients and physicians to prioritize therapy options for recurrent and refractory ovarian cancer by providing information and interpretation about the tumor molecular profile;
  • Helping patients find clinical trials for which they may be eligible based on the molecular characteristics of their tumor;
  • Educating patients and physicians about the value of molecular profiling in ovarian cancer diagnosis and treatment;
  • Partnering on research that may expedite the clinical development of novel targeted agents for ovarian cancer.